Dr. Derick Mitchell:

I agree with Mr. Watt. An additional element we would like is probably more transparency in the process. It has been very frustrating to have to go to multiple different sources to get the facts about the delays. A number of studies have been performed but the system does not seem to release information readily. From a patient perspective to know where a particular drug is in the process at any stage would be one thing, but also to know which stakeholder has been holding up the process would be very beneficial as well.